PBPK and PD modelling to support first-in-human predictions for challenging modalities | An ISSX 2024 Short Course

PBPK and PD modelling to support first-in-human predictions for challenging modalities | An ISSX 2024 Short Course

  • Register
    • Non-member - $300
    • Member - $200
    • Student - $75
    • Premier - Free!

    Continue

Co-chairs: Daniel Scotcher, University of Manchester, UK and Jaydeep Yadav, Merck, USA

  • FiH dose predictions for protein degraders with PKPD modelling
    Jaydeep Yadav, Merck & Co, USA
  • Translational strategies for multi-specific antibodies (t-cell engagers) in oncology/ immunology
    Fei Hua, Certara, USA
  • Modelling of oligonucleotides and RNAi therapeutics
    Vivaswath Ayyar, GSK, USA
  • Applications and considerations of mechanistic modeling in regulatory decision process
    Yuching Yang, Cary, NC, USA

Key:

Complete
Failed
Available
Locked
Applications and considerations of mechanistic modeling in regulatory decision process | Yuching Yang, Cary, NC, USA
Open to view video.
Open to view video. This short course introduces key considerations and data requirements for PBPK and PK/PD modeling of challenging drug modalities, emphasizing how computational approaches support decision making in drug discovery and development.
You must register to access.
Modelling of oligonucleotides and RNAi therapeutics | Vivaswath Ayyar, GSK, USA
Open to view video.
Open to view video. This short course introduces key considerations and data requirements for PBPK and PK/PD modeling of challenging drug modalities, emphasizing how computational approaches support decision making in drug discovery and development.
You must register to access.
Human Dose predictions for protein degraders with PKPD modelling
Open to view video.
Open to view video. This short course introduces key considerations and data requirements for PBPK and PK/PD modeling of challenging drug modalities, emphasizing how computational approaches support decision making in drug discovery and development.
You must register to access.
Translational strategies for multi-specific antibodies (t-cell engagers) in oncology/ immunology | Fei Hua, Certara, USA
Open to view video.
Open to view video. This short course introduces key considerations and data requirements for PBPK and PK/PD modeling of challenging drug modalities, emphasizing how computational approaches support decision making in drug discovery and development
You must register to access.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Certificate of completion
You must register to access.